Cypress Capital Management LLC Bristol Myers Squibb CO Transaction History

Cypress Capital Management LLC

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 10, 2022	SELL	$72.62 - $79.98 $3,631 - $3,999	-50 Reduced 1.25%	3,953 $304,000
Q1 2022 May 13, 2022	SELL	$61.48 - $73.72 $49,184 - $58,976	-800 Reduced 16.66%	4,003 $292,000
Q4 2021 Feb 22, 2022	SELL	$53.63 - $62.52 $2,198 - $2,563	-41 Reduced 0.85%	4,803 $299,000
Q1 2021 May 12, 2021	SELL	$59.34 - $66.74 $50,498 - $56,795	-851 Reduced 14.94%	4,844 $306,000
Q4 2020 Feb 08, 2021	SELL	$57.74 - $65.43 $89,497 - $101,416	-1,550 Reduced 21.39%	5,695 $353,000
Q2 2020 Aug 13, 2020	SELL	$54.82 - $64.09 $9,867 - $11,536	-180 Reduced 2.42%	7,245 $426,000
Q4 2019 Feb 14, 2020	SELL	$49.21 - $64.19 $8.53 Million - $11.1 Million	-173,335 Reduced 95.89%	7,425 $477,000
Q3 2019 Nov 01, 2019	BUY	$42.77 - $50.71 $7.73 Million - $9.17 Million	180,760 New	180,760 $9.17 Million
Q2 2019 Aug 05, 2019	SELL	$44.62 - $49.34 $6.89 Million - $7.61 Million	-154,335 Closed	0 $0
Q2 2019 Aug 05, 2019	BUY	$44.62 - $49.34 $1.2 Million - $1.33 Million	26,990 Added 21.19%	154,335 $7 Million
Q1 2019 May 06, 2019	BUY	$45.12 - $53.8 $562,872 - $671,155	12,475 Added 10.86%	127,345 $6.08 Million
Q4 2018 Feb 05, 2019	BUY	$48.76 - $63.23 $5.28 Million - $6.85 Million	108,320 Added 1653.74%	114,870 $5.97 Million
Q3 2018 Nov 09, 2018	BUY	$55.19 - $62.25 $5,519 - $6,225	100 Added 1.55%	6,550 $407,000
Q4 2017 Feb 07, 2018	SELL	$59.94 - $65.35 $11,988 - $13,069	-200 Reduced 3.01%	6,450 $395,000
Q2 2017 Aug 15, 2017	BUY	N/A	6,650	6,650 $371,000

2,428

1.5B

29.7M

32.2M

Ticker BMY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 2,126,160,000
Market Cap $113B
Description
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...

Get notified when there are updates to the investment portfolio of Cypress Capital Management LLC, based on Form 13F filings with the SEC.

Stay updated on Cypress Capital Management LLC with notifications on news.